SEARCH RESULTS FOR:
Francisco Rubio
PRESIDENT, KEMIKALS
Kemilkas is a Mexican distributor with a focus on innovation and environmental sustainability.
Nigel Ferguson
MANAGING DIRECTOR, AVZ MINERALS
MACIG Copperbelt & Angola 2021
AVZ Minerals talks about setting up its Manono lithium and tin project in DRC.
Allan Yong
SENIOR VICE PRESIDENT & MARKET HEAD, SOUTH EAST ASIA, ECOLAB
Ecolab is a global leader in water, hygiene and infection prevention solutions and services that protect people and vital resources.
Sean Spencer
VICE PRESIDENT AND MANAGING DIRECTOR, AFTON CHEMICAL ASIA
Afton Chemical Asia Pacific describes how its focus and products are adapting to the changing requirements of a global drive towards environmental sustainability.
William H. Lewis
CHAIR & CEO, INSMED
2020 has been a transformative year for Insmed that is now undertaking three exciting programs for rare and serious diseases.
Christiana Bardon
PORTFOLIO MANAGER, BURRAGE CAPITAL, MANAGING DIRECTOR, ONCOLOGY IMPACT FUND, MPM CAPITAL
Burrage Capital speaks to GBR about the current wave of enthusiasm investors are showing towards biotech.
Wilson Miranda
GENERAL MANAGER, CONFIPETROL ANDINA
Confipetrol Andina comments on opportunities for 2021 in Peru’s mining sector.
Michael W. Scherb
FOUNDER & CEO, APPIAN CAPITAL ADVISORY LLP
Appian Capital Advisory has raised US$775 million for its second fund, Appian Natural Resources Fund II.
Dale Clayton
MANAGING DIRECTOR, LIEBHERR CHILE
Liebherr Chile explains to GBR its plans for supplying the Chilean mining market.
Mario Theurl & Dirk Pförtner
TECHNICAL MANAGER STRABAG ZÜBLIN & COMMERCIAL MANAGER, STRABAG ZÜBLIN CHILE
Strabag Züblin explains how it is deploying technology at Chile’s large underground mines to ensure safety and productivity.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
